CN103570687B - 一种奥美拉唑钠晶体化合物 - Google Patents
一种奥美拉唑钠晶体化合物 Download PDFInfo
- Publication number
- CN103570687B CN103570687B CN201310572070.XA CN201310572070A CN103570687B CN 103570687 B CN103570687 B CN 103570687B CN 201310572070 A CN201310572070 A CN 201310572070A CN 103570687 B CN103570687 B CN 103570687B
- Authority
- CN
- China
- Prior art keywords
- omeprazole sodium
- compound
- omeprazole
- sodium compound
- dmf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940063517 omeprazole sodium Drugs 0.000 title claims abstract description 81
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 title claims abstract description 81
- 150000001875 compounds Chemical class 0.000 title abstract description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 238000005259 measurement Methods 0.000 claims abstract description 6
- 239000012047 saturated solution Substances 0.000 claims abstract description 5
- 238000007789 sealing Methods 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 3
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 8
- 229910017488 Cu K Inorganic materials 0.000 claims description 5
- 229910017541 Cu-K Inorganic materials 0.000 claims description 5
- 230000005260 alpha ray Effects 0.000 claims description 5
- 239000012043 crude product Substances 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract description 13
- 238000000634 powder X-ray diffraction Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 230000027119 gastric acid secretion Effects 0.000 description 3
- 210000001711 oxyntic cell Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CAVZBWFUMSXZFB-LJWNLINESA-N Amogastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)OC(C)(C)CC)C(N)=O)C1=CC=CC=C1 CAVZBWFUMSXZFB-LJWNLINESA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108700042255 amogastrin Proteins 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 229950002342 bisfentidine Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- FXJAOWANXXJWGJ-UHFFFAOYSA-N n-[4-(2-methyl-1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=C(C)N1 FXJAOWANXXJWGJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
样品1 | 样品2 | 样品3 | 样品4 | 样品5 | 样品6 | 样品7 | 样品8 | |
H | 2.03cm | 1.80cm | 3.22cm | 3.33cm | 2.70cm | 3.11cm | 3.0cm | 3.33cm |
R | 3cm | 3cm | 3cm | 3cm | 3cm | 3cm | 3cm | 3cm |
α | 34° | 31° | 47° | 48° | 42° | 46° | 45° | 48° |
制剂 | DMF | 乙醚 | 其它有关物质 |
实施例1产品 | 符合规定 | 符合规定 | 符合规定 |
实施例2产品 | 符合规定 | 符合规定 | 符合规定 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310572070.XA CN103570687B (zh) | 2013-11-15 | 2013-11-15 | 一种奥美拉唑钠晶体化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310572070.XA CN103570687B (zh) | 2013-11-15 | 2013-11-15 | 一种奥美拉唑钠晶体化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103570687A CN103570687A (zh) | 2014-02-12 |
CN103570687B true CN103570687B (zh) | 2015-01-07 |
Family
ID=50043472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310572070.XA Active CN103570687B (zh) | 2013-11-15 | 2013-11-15 | 一种奥美拉唑钠晶体化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103570687B (zh) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE510643C2 (sv) * | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
US20030212274A1 (en) * | 2000-05-15 | 2003-11-13 | Bakthavathsalan Vijayaraghavan | Novel amorphous form of omeprazole salts |
US20040224987A1 (en) * | 2003-03-13 | 2004-11-11 | Dr. Reddy's Laboratories Limited | Crystalline form C of omeprazole sodium and the related process of its preparation, a crystalline form D of omeprazole sodium and the related process of its preparation, and a process for preparation of crystalline form a of omeprazole sodium |
WO2006073779A1 (en) * | 2004-12-30 | 2006-07-13 | Transform Phamaceuticals, Inc. | Novel omeprazole forms and related methods |
ES2432563T3 (es) * | 2005-06-08 | 2013-12-04 | Lek Pharmaceuticals D.D. | Solvato cristalino de omeprazol sódico |
CN101412710B (zh) * | 2008-12-16 | 2010-04-21 | 海南百那医药发展有限公司 | 一种奥美拉唑钠化合物及其制法 |
CN102351846B (zh) * | 2011-09-07 | 2012-08-22 | 周晓东 | 一种新的奥美拉唑钠化合物及其药物组合物 |
CN102827147B (zh) * | 2012-09-13 | 2013-08-07 | 山东罗欣药业股份有限公司 | 一种奥美拉唑钠晶体化合物及含有该晶体化合物的药物组合物 |
CN103012371B (zh) * | 2013-01-05 | 2014-02-12 | 宁辉 | 奥美拉唑钠结晶化合物、其制备方法及其药物组合物 |
CN103288801B (zh) * | 2013-06-04 | 2016-01-20 | 四川百利药业有限责任公司 | 一种高纯度埃索美拉唑钠的制备方法 |
-
2013
- 2013-11-15 CN CN201310572070.XA patent/CN103570687B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103570687A (zh) | 2014-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105616362B (zh) | 一种注射用帕瑞昔布钠药物组合物及其制备方法 | |
CN101987099A (zh) | 注射用奥美拉唑钠及其制备方法 | |
CN103054797B (zh) | 一种泮托拉唑钠的药物组合物及其制备方法 | |
CN103570687B (zh) | 一种奥美拉唑钠晶体化合物 | |
CN105055342A (zh) | 一种治疗消化性溃疡的药物艾普拉唑钠组合物冻干粉针剂 | |
CN104922080A (zh) | 治疗消化系统疾病的药物艾普拉唑钠冻干粉针剂组合物 | |
CN104961681B (zh) | 卡博替尼的粘酸盐及其晶型 | |
CN102351812B (zh) | 甲磺酸桂哌齐特晶型iii及其制备方法 | |
CN104856993A (zh) | 治疗消化系统疾病的药物泮托拉唑钠冻干粉针剂组合物 | |
CN104784146A (zh) | 一种治疗消化性溃疡的药物艾普拉唑钠组合物 | |
CN105753869B (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
CN105106112A (zh) | 一种降压药乌拉地尔组合物水针剂 | |
CN105193746A (zh) | 一种降压药乌拉地尔组合物冻干粉针剂 | |
CN103288799B (zh) | 兰索拉唑的合成方法及由该方法合成的兰索拉唑 | |
CN105055411A (zh) | 一种治疗胃溃疡的药物泮托拉唑钠组合物 | |
CN105030772A (zh) | 一种治疗消化性疾病的药物艾普拉唑钠组合物 | |
CN105801647B (zh) | 甲钴胺化合物及含其制剂与制备方法 | |
CN109160931A (zh) | 一种1/2水胞磷胆碱钠化合物 | |
CN105085548A (zh) | 一种治疗感染性疾病的药物头孢替安组合物 | |
CN104447694A (zh) | 合成兰索拉唑的中间体原料 | |
CN101735172A (zh) | 桂哌齐特一水合物、晶型及其制备方法 | |
CN105732642A (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
CN105055343A (zh) | 一种治疗胃病的药物艾普拉唑钠组合物冻干粉针剂 | |
CN104447698B (zh) | 奥美拉唑钠1.5倍结晶水化合物 | |
CN104356042B (zh) | 一种固体形式的奥拉西坦及其制备方法、用途和药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160620 Address after: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Patentee after: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: Beijing Yuekangyuantong Pharmaceutical Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Patentee before: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee after: Beijing Yuekangyuantong Pharmaceutical Co.,Ltd. Patentee after: Yuekang Pharmaceutical Group Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee before: Beijing Yuekangyuantong Pharmaceutical Co.,Ltd. Patentee before: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee after: Beijing Yuantong Kangbai Pharmaceutical Co.,Ltd. Patentee after: Yuekang Pharmaceutical Group Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee before: Beijing Yuekangyuantong Pharmaceutical Co.,Ltd. Patentee before: Yuekang Pharmaceutical Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200622 Address after: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Patentee after: Yuekang Pharmaceutical Group Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee before: Beijing Yuantong Kangbai Pharmaceutical Co.,Ltd. Patentee before: Yuekang Pharmaceutical Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210707 Address after: 101111 room 105, 1st floor, building 3, courtyard 11, kechuangqi street, Tongzhou District, Beijing Patentee after: Beijing Kechuang Dingcheng Pharmaceutical Technology Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Patentee before: Yuekang Pharmaceutical Group Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 101111 room 105, 1st floor, building 3, courtyard 11, kechuangqi street, Tongzhou District, Beijing Patentee after: Beijing Yuelaixin Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: 101111 room 105, 1st floor, building 3, courtyard 11, kechuangqi street, Tongzhou District, Beijing Patentee before: Beijing Kechuang Dingcheng Pharmaceutical Technology Co.,Ltd. Country or region before: China |